Evidence map›Paper›PMID 29393351›Full record

ArticleInternational journal of molecular medicine2018

Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension.

Jia Liu, Jiamei Liu, Linying Shi, Fan Zhang, Liping Yu, Xinchun Yang, Jun Cai

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jia LiuDepartment of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Jiamei LiuDepartment of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Linying ShiDepartment of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Fan ZhangDepartment of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Liping YuDepartment of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Xinchun YangDepartment of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Jun CaiDepartment of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Capital Medical University · CNBeijing Chao-Yang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to explore microRNA-126 (miR-126) as a novel therapeutic target for primary hypertension. The lentiviral vector containing human immunodeficiency virus 1 (HIV‑1), the miR‑126 gene knockdown viral vector (lenti-miR-126-KD), and control lentiviral vector (lenti‑scramble‑miR) were constructed. Spontaneously hypertensive rats were randomly divided into 4 groups, which received a high dose of lenti‑miR‑126‑KD (1x108, n=5), low dose of lenti‑miR‑126‑KD (1x107, n=6), scramble‑miR (5x107, n=6), and PBS (n=6). Lentiviral vectors were injected into the tail vein. Data on the systolic blood pressure, diastolic pressure, mean arterial pressure, and heart rate were collected weekly. After 8 weeks of virus administration, the distribution of lentiviral vectors in different tissues was observed by fluorescence microscopy. Picric acid Sirius red and H&E staining were used to observe the target organ damage, and the ELISA kit was used to determine the serum nitric oxide (NO) content. The lentiviral vector was found to be constructed successfully. Eight weeks after the lentiviral vector injection, green fluorescent protein was observed in different tissues in each group. The blood pressure and heart rate were not significantly altered after lentiviral vector injection (P>0.05). No significant differences in the heart‑to‑body weight ratio among the four groups were observed (P=0.23). Picric acid Sirius red and H&E staining revealed that there was no significant difference in morphology among the four groups. No significant difference in the serum NO level among the four groups was noted (P=0.23). The miR‑126 gene knockdown lentiviral vector was constructed successfully. No significant antihypertensive effect was observed by the knockdown of miR‑126 for the treatment of primary hypertension. The target organs were not protected significantly after the treatment. The increased level of miR‑126 expression in hypertensive patients may be due to a compensatory mechanism.

Indexed as

Genetic TherapyAnimalsFemaleGene Knockdown TechniquesGenetic VectorsHumansHypertensionLentivirusMaleMicroRNAsRats, Inbred SHRUp-RegulationMicroRNAsMIRN126 microRNA, humanMIRN126 microRNA, rat

Identifiers

PMID29393351
PMCPMC5810200
OpenAlexW2788358412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.